1. Denmark Stocks

  2. •

    Health technology

  3. •

    Medical specialties
ChemoMetec A/S

ChemoMetec A/S

594.00
DKK
+12.00
(+2.06%)
6.33BMarket Cap
Feb 03Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2.6
3.91
5.44
5.76
7.26
11.28
12.7
16.15
24.62
25.54
23.44
28.48
29.37
- -
Basic EPS, GAAP
0.07
0.51
0.67
0.48
1.17
2.69
3.51
5.08
9.16
10.27
7.83
10.04
11.6
- -
Free Cash Flow per Basic Share
-0.08
0.28
-0.81
-0.05
0.58
2.01
2.69
4.79
6.95
6.51
4.91
8.2
6.55
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
21.16
1.5
4
- -
6
4
7
- -
Book Value per Share
2.56
2.66
3.27
3.7
4.75
11
11.65
15.23
20.53
30.63
32.48
39.54
41.94
41.94
Tangible Book Value per Share
1.17
1.31
1.76
1.97
2.27
8.14
8.7
11.9
16.65
26.05
27.05
30.74
29.9
29.9
Basic Weighted Avg Shares
17
16
16
16
16
16
17
17
17
17
17
17
17
17
Sales/Revenue/Turnover
45
61
85
90
113
176
214
281
428
444
408
496
511
- -
Operating Margin (%)
3.64
9.52
18.87
11.28
21.55
30.78
36.05
41.57
47.33
51.9
41.43
47.73
49.11
- -
Depreciation Expense
6
6
7
5
6
11
15
20
20
20
17
22
30
- -
Net Income, GAAP
1
8
10
7
18
42
59
88
159
179
136
175
202
- -
Effective Tax Rate (%)
- -
- -
23.88
13.48
21.83
22.09
22.07
21.63
21.53
22.44
22.82
22.36
21.82
- -
Profit Margin (%)
2.54
12.98
12.3
8.29
16.16
23.84
27.63
31.43
37.23
40.2
33.41
35.25
39.49
- -
Working Capital
16
17
22
20
29
100
121
172
216
373
391
411
397
397
LT Debt
1
5
17
12
18
- -
1
1
5
4
1
3
2
2
Total Equity
45
46
57
64
73
173
203
265
357
533
565
688
725
725
Return on Invested Capital (%)
3.58
- -
18.16
10.89
21.13
28.9
29.22
36.18
45.2
35.75
22.23
27.57
26.19
- -
Return on Capital (%)
2.76
- -
17.11
10.17
21.09
29.73
30.26
37.71
50.89
39.71
24.59
27.71
28.37
- -
Return on Common Equity (%)
2.62
17.49
20.32
12.35
26.52
33.97
31.46
37.78
51.26
40.14
24.82
27.88
28.56
- -

Capital Structure

DKK

•

in mil. unless spec.
Jun'25
Dec'26
Jun'26
ST Debt
3
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
10,046
11,895
6,333

Working Capital

DKK

•

in mil. unless spec.
Jun'25
Dec'26
Jun'26
Total Current Assets
555
484
525
Cash, Cash Equivalents & STI
342
275
294
Accounts Receivable, Net
80
93
90
Inventories
121
107
126
Total Current Liabilities
144
123
128
Payables & Accruals
- -
- -
- -
ST Debt
3
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

DKK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.9%
23.45%
5.43%
Free Cash Flow
-83.26%
12.23%
-20.15%
Net Income, GAAP
44.77%
22.51%
15.53%
Sales/Revenue/Turnover
21.23%
14.5%
3.12%
Total Cash Common Dividend
- -
- -
75.02%

Semi-annual Revenue

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
408
2025
- -
- -
496
2026
- -
- -
511

Semi-annual Earnings Per Share

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
7.83
2025
- -
- -
10.04
2026
- -
- -
11.6

Semi-annual Dividends Per Share

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
6
2025
- -
- -
4
2026
- -
- -
7

Company Description

Company Profile APIChatGPT
CEO
Martin Helbo Behrens
Full Time Employees
174
Sector
Health technology
Industry
Medical specialties
Address
Gydevang 43 Allerod CR Denmark 3450
IPO Date
Dec 20, 2006
Website
chemometec.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
ChemoMetec A/S develops, manufactures and sells analytical instruments and consumables for cell counting and analysis. The company offers the NucleoCounter NC-202 cell counter, NucleoCounter NC-3000 advanced image cytometer, XcytoMatic 30, XcytoMatic 40 and XcytoMatic 50 high-throughput cell density analyzers for bioprocessing; Via2-Cassette consumables; reagents, lysis buffers and slides; and accessories including software, cables, power supplies and labware, as well as service, validation plans and training. ChemoMetec serves biotech, pharmaceutical and academic customers in cell and gene therapy, cancer and stem cell research, pharmaceutical development and manufacturing, and quality control for animal semen, milk and beer. The company operates worldwide, including in the United States, Canada and Europe. Founded in 1997, ChemoMetec is headquartered in Allerød, Denmark, and owns subsidiary ChemoMetec USA Inc. In 2024, ChemoMetec acquired Belgian competitor Ovizio Imaging Systems SA for EUR 2.83 million to integrate its imaging technology into XcytoMatic products and strengthen its automated bioprocessing position; the company launched the XcytoMatic 40 to enter high-throughput bioprocessing markets, followed by XcytoMatic 30 and XcytoMatic 50 on the same platform to meet cell and gene therapy automation demand; and reported 22% revenue growth to DKK 495.6 million for fiscal 2024/25 with 39% EBITDA growth to DKK 258 million.